AU2005208552A1 - Use of aerosolized antithrombin to treat acute lung injury - Google Patents

Use of aerosolized antithrombin to treat acute lung injury Download PDF

Info

Publication number
AU2005208552A1
AU2005208552A1 AU2005208552A AU2005208552A AU2005208552A1 AU 2005208552 A1 AU2005208552 A1 AU 2005208552A1 AU 2005208552 A AU2005208552 A AU 2005208552A AU 2005208552 A AU2005208552 A AU 2005208552A AU 2005208552 A1 AU2005208552 A1 AU 2005208552A1
Authority
AU
Australia
Prior art keywords
atiii
lung injury
antithrombin
protein
argatroban
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005208552A
Other languages
English (en)
Inventor
Robert A. Cox
Perenlei Enkhbaatar
Hal A. Hawkins
Kazunori Murakami
Daniel L. Traber
Lillian D. Traber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
rEVO Biologics Inc
Original Assignee
GTC Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GTC Biotherapeutics Inc filed Critical GTC Biotherapeutics Inc
Publication of AU2005208552A1 publication Critical patent/AU2005208552A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2005208552A 2004-01-23 2005-01-14 Use of aerosolized antithrombin to treat acute lung injury Abandoned AU2005208552A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53867804P 2004-01-23 2004-01-23
US60/538,678 2004-01-23
US11/034,590 2005-01-13
US11/034,590 US20050169908A1 (en) 2004-01-23 2005-01-13 Use of aerosolized antithrombin to treat acute lung injury
PCT/US2005/001238 WO2005072139A2 (en) 2004-01-23 2005-01-14 Use of aerosolized antithrombin to treat acute lung injury

Publications (1)

Publication Number Publication Date
AU2005208552A1 true AU2005208552A1 (en) 2005-08-11

Family

ID=34810485

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005208552A Abandoned AU2005208552A1 (en) 2004-01-23 2005-01-14 Use of aerosolized antithrombin to treat acute lung injury

Country Status (8)

Country Link
US (1) US20050169908A1 (enExample)
EP (1) EP1713500A2 (enExample)
JP (1) JP4854519B2 (enExample)
KR (1) KR20060127992A (enExample)
AU (1) AU2005208552A1 (enExample)
CA (1) CA2553758A1 (enExample)
IL (1) IL177028A0 (enExample)
WO (1) WO2005072139A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005216044B2 (en) * 2004-02-20 2011-07-14 Board Of Regents, The University Of Texas System Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535487A (en) * 2002-04-01 2008-12-24 Univ Texas Medical Branch Administration of ATIII by inhalation provides more efficient treatment of lung disorders such as lung inflammation and injury than intravenous administration
US20050245444A1 (en) * 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
US20060121004A1 (en) * 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
WO2012090067A1 (en) 2010-12-30 2012-07-05 Lfb Biotechnologies Glycols as pathogen inactivating agents
WO2014089327A1 (en) * 2012-12-05 2014-06-12 National Jewish Health Treatment for airway cast obstruction
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
WO2014140927A2 (en) 2013-02-13 2014-09-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
ES2793176T3 (es) 2013-07-05 2020-11-13 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa Matriz de cromografía de afinidad
CA2928759A1 (en) 2013-11-04 2015-05-07 Board Of Regents, The University Of Texas System Compositions and methods for administration of an enzyme to a subject's airway
WO2016118625A1 (en) * 2015-01-20 2016-07-28 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
WO2016179447A1 (en) * 2015-05-06 2016-11-10 Board Of Regents, The University Of Texas System Compositions and methods for administration of an enzyme to a subject's airway
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127347A (en) * 1994-01-12 2000-10-03 Univ Michigan Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
NZ535487A (en) * 2002-04-01 2008-12-24 Univ Texas Medical Branch Administration of ATIII by inhalation provides more efficient treatment of lung disorders such as lung inflammation and injury than intravenous administration
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005216044B2 (en) * 2004-02-20 2011-07-14 Board Of Regents, The University Of Texas System Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Also Published As

Publication number Publication date
JP2007518801A (ja) 2007-07-12
US20050169908A1 (en) 2005-08-04
KR20060127992A (ko) 2006-12-13
IL177028A0 (en) 2006-12-10
WO2005072139A2 (en) 2005-08-11
CA2553758A1 (en) 2005-08-11
WO2005072139A3 (en) 2006-01-05
EP1713500A2 (en) 2006-10-25
JP4854519B2 (ja) 2012-01-18

Similar Documents

Publication Publication Date Title
US20110070167A1 (en) Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
Lewis Expanding the clinical indications for α1-antitrypsin therapy
Gallagher et al. Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection
US20050169908A1 (en) Use of aerosolized antithrombin to treat acute lung injury
Saadi et al. Regional manifestations and control of the immune system
Alam et al. Role of the endogenous elastase inhibitor, elafin, in cardiovascular injury: from epithelium to endothelium
US7642234B2 (en) Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
Carmeliet et al. Gene manipulation and transfer of the plasminogen and coagulation system in mice
Levi et al. Plasma and plasma components in the management of disseminated intravascular coagulation
CA2879763C (en) The use of antithrombin in extracorporeal membrane oxygenation
Lee et al. Protective effects of transgenic human endothelial protein C receptor expression in murine models of transplantation
US20080004212A1 (en) Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
US20050245444A1 (en) Method of using recombinant human antithrombin for neurocognitive disorders
Turner Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies
AU2011202575A1 (en) Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
US20150071909A1 (en) Methods and compositions for reducing the incidence of post-surgical adhesions
JPH08502028A (ja) インターロイキン−６を含有する薬剤組成物、及び消耗性凝血出血疾患の治療への該薬剤組成物の使用
CN1946419A (zh) 使用气溶胶化抗凝血酶治疗急性肺损伤
CA2499458A1 (en) Protein s protects the nervous system from injury
WO2005112968A2 (en) Method of using recombinant human antithrombin for neurocognitive disorders
Chan Characterization of murine factor VII deficiency and its additional effects on tissue factor pathway inhibitor and protein C-deficient mice

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period